BiosyentTSXV:RX +0.42%99 OCF Yield % is 7.58 as of Jul. 04, 2026, which is 45% above its 10-year median of 5.22. GuruFocus rates TSXV:RX with a GF Score™ of 99/100 and a GF Value™ of C$16.31 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Biosyent ranks better than 71.7% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Biosyent OCF Yield % Related Terms
Biosyent OCF Yield % Historical Data
* Premium members only.
The historical data trend for Biosyent's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biosyent OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biosyent's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Biosyent's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biosyent (TSXV:RX) has a OCF Yield % of 7.58 as of Jul. 04, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Biosyent and its competitors. This is 45% above median its historical median of 5.22. Over the past decade, Biosyent's OCF Yield % has ranged from 1.95 to 10.49. According to the industry distribution chart, Biosyent ranks #285 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 28.3%.
Is Biosyent's OCF Yield % too high?
Biosyent's current OCF Yield % of 7.58 is 45% above median its 10-year median of 5.22. Over the past 10 years, this metric has ranged from a low of 1.95 to a high of 10.49. The Drug Manufacturers industry median OCF Yield % is 3.43. Biosyent's value of 7.58 is 121% above this industry median. Based on the distribution chart, Biosyent ranks #285 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Biosyent has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biosyent's OCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biosyent ranks #285 out of 1007 companies for OCF Yield %. This puts Biosyent in the upper half of its industry. The industry median OCF Yield % is 3.43. Biosyent's value of 7.58 is 121% above this benchmark. Historically, Biosyent's own OCF Yield % has ranged from 1.95 to 10.49 over the past decade. While the company's 10-year median is 5.22 vs. the industry median of 3.43, Biosyent has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.43, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biosyent's current OCF Yield % of 7.58 is 121% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Biosyent and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biosyent's current OCF Yield % is 7.58, which is 45% above median its own 10-year median of 5.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosyent stock overvalued right now?
Based on GuruFocus' analysis, Biosyent (TSXV:RX) is currently considered Modestly Undervalued. The stock's GF Value™ is C$16.31, compared to a current price of C$14.50 — trading 11.1% below its estimated fair value. The current OCF Yield % is 7.58, which is 45% above median its 10-year median of 5.22 and 121% above the Drug Manufacturers industry median of 3.43. Biosyent's overall GF Score™ is 99/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Biosyent (TSXV:RX), the current OCF Yield % is 7.58 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biosyent (TSXV:RX) Overvalued in 2026?
Based on GuruFocus' analysis, Biosyent stock appears to be undervalued.
The current stock price of C$14.50 is trading 11.1% below its estimated GF Value™ of C$16.31.
GuruFocus considers Biosyent to be Modestly Undervalued.
Key valuation signals for TSXV:RX:
OCF Yield %: 7.58 (45% above median its 10-year median of 5.22)
GF Value™: C$16.31 vs. price of C$14.50 (11.1% below fair value)
Industry Position: 121% above the Drug Manufacturers median (#285 of 1007)
No single metric tells the full story. See the TSXV:RX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It markets and delivers a diverse range of healthcare products, including over-the-counter, behind-the-counter, and prescription options. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX Pd, Inofolic, Gelclair, Cathejell, RepaGyn, Proktis-M, and Tibella. The company derives revenue from pharmaceutical and insecticide business. Geographically, it derives maximum revenue from Canada and also has its presence internationally.
99GF Score
Get the complete analysis for TSXV:RX
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:RX has been successfully added to your 
